<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891005</url>
  </required_header>
  <id_info>
    <org_study_id>Branden-123</org_study_id>
    <nct_id>NCT02891005</nct_id>
  </id_info>
  <brief_title>Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)</brief_title>
  <official_title>A Multicenter, Prospective and Randomized Controlled Clinical Study (VasoguardTM Trial I) That Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Branden Med.Device Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Branden Med.Device Co.,Ltd</source>
  <brief_summary>
    <textblock>
      Study Purpose The safety and efficacy of paclitaxel controlled release balloon catheter
      VasoguardTM in treatment of small vessel lesion.

      Study Group Experimental group: paclitaxel controlled release balloon catheter (VasoguardTM)
      Control group: common balloon catheter (Maverick2)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss</measure>
    <time_frame>at 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Device Success</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Operation Success</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the target lesion in-segment restenosis (%) at 9mm</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical-driven target lesion revascularization (TLR) and target vessel revascularization (TVR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Small Vessel Lesion</condition>
  <arm_group>
    <arm_group_label>paclitaxel controlled release balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with paclitaxel controlled release balloon catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>common balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with common balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel controlled release balloon catheter (VasoguardTM)</intervention_name>
    <description>paclitaxel controlled release balloon catheter implantation for small vessel lesion</description>
    <arm_group_label>paclitaxel controlled release balloon catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>common balloon catheter (Maverick2)</intervention_name>
    <description>common balloon catheter implantation for small vessel lesion</description>
    <arm_group_label>common balloon catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject need 18 to 80 years of aged male or non-pregnant women; Subject has stable anina
        pectoris, or unstable anina pectoris, or old myocardial infarction patients, or ischemia
        with evidence but without symptom; Subject has a life expectancy of more than 2 years;
        Lesion vessel reference diameter is less than or equal to 2.5mm, target lesion length is
        less than or equal to 40mm; Target lesion stenosis is equal or greater than 70% or 50% and
        with ischemia; Single or two coronary small vessel lesions in situ; Subject can understand
        the trail purpose, sign informed consent voluntarily, agree to accept clinical telephone
        follow-up and angiographic follow-up at 9 months; Target lesion can be pre-expanded
        successfully (Guide wire can get through lesion, balloon pre-expand the remnant stenosis of
        vessel lumen is less or equal to 50%, without current limiting interlayer and thrombosis).

        Exclusion Criteria:

        Patient that in the opinion of the investigator is not appropriate for this trail;
        Pregnancy and lactation female patients; Patient has a life expectancy of less than 2
        years; Severe congestive heart failure or NYHA IV heart failure; Patient who have bleeding
        constitution, cannot use antithrombotic and antiplatelet drugs; Patient that happened acute
        myocardial infarction within a week; Patient who happened stroke within six months; Patient
        who with severe renal failure (GFR≤30ml/Min); Patient has received heart transplantation;
        Patient who cannot tolerate aspirin and / or P2Y12 receptor inhibitor drugs; Patient who
        has allergy to paclitaxel, PLGA or contrast agent; Peptic ulcer or gastrointestinal
        bleeding within the prior 6 months; Patients who are participating in another drug or
        device clinical trail, which have not completed the primary endpoint follow- up period.

        Angiographic relevant： Merge three or more coronary small vessel lesions; Target vessel
        with extensive thrombosis evidence; Restenosis of vein graft after bypass surgery; Target
        lesion proximal exist seriously distorted or severe calcified lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuxia Yin</last_name>
    <phone>18596253015</phone>
    <email>yinyx@brandentech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junbo Ge</last_name>
      <phone>13901977506</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

